D. E. Shaw Entities Reduce Stake in Gossamer Bio by Over $900K Post-Debt Exchange
GOSS sits 21% above its 52-week low of $0.14.
Summary
D. E. Shaw & Co. entities have significantly reduced their stake in Gossamer Bio, selling over $900,000 in shares following the company's distressed debt exchange.
Key Events · Ownership and Investor Activity · GOSS
-
Significant Share Sales by Institutional Investor
D. E. Shaw & Co. entities sold 5,445,469 common shares between June 12 and July 1, 2026, for an estimated value of over $925,000.
-
Stake Reduction Post-Debt Exchange
These sales occurred after Gossamer Bio completed a distressed debt exchange, converting $181.05 million of convertible notes into equity, which resulted in massive dilution.
-
Current Beneficial Ownership
Following these transactions, D. E. Shaw & Co., L.P. and related entities beneficially own 40,630,726 shares, representing 8.3% of the outstanding common stock.
Analysis · GOSS · Life Sciences
D. E. Shaw & Co. entities, significant institutional investors, have sold approximately $925,000 worth of Gossamer Bio common stock over the past month. This reduction in stake, representing over 1% of the company's market capitalization and 13% of their prior holdings, occurs shortly after the company completed a highly dilutive distressed debt exchange. The sales by a major investor suggest a lack of confidence following the recent financial restructuring.
At the time of this filing, GOSS was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $82M. The 52-week trading range was $0.14 to $3.87. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.